Page 1097 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 60 Myelodysplastic Syndromes 969.e11

451. Manoharan A: Low-dose cytarabine therapy in hypoplastic acute phase II clinical trial with a differentiation-inducing agent. Blood
leukemia. N Engl J Med 309(26):1652–1653, 1983. 80(10):2604–2609, 1992.
452. Deeg HJ, Gotlib J, Beckham C, et al: Soluble TNF receptor fusion 473. Essers MAG, Offner S, Blanco-Bose WE, et al: IFNalpha activates
protein (etanercept) for the treatment of myelodysplastic syndrome: a dormant haematopoietic stem cells in vivo. Nature 458(7240):904–908,
pilot study. Leukemia 16(2):162–164, 2002. 2009.
453. Rosenfeld C, Bedell C: Pilot study of recombinant human soluble 474. Walter D, Lier A, Geiselhart A, et al: Exit from dormancy provokes
tumor necrosis factor receptor (TNFR:Fc) in patients with low risk DNA-damage-induced attrition in haematopoietic stem cells. Nature
myelodysplastic syndrome. Leuk Res 26(8):721–724, 2002. 520:549–552, 2015.
454. Scott BL, Ramakrishnan A, Fosdal M, et al: Anti-thymocyte globulin 475. List A, Beran M, DiPersio J, et al: Opportunities for Trisenox (arsenic
plus etanercept as therapy for myelodysplastic syndromes (MDS): a trioxide) in the treatment of myelodysplastic syndromes. Leukemia
phase II study. Br J Haematol 149(5):706–710, 2010. 17(8):1499–1507, 2003.
455. Stasi R, Amadori S: Infliximab chimaeric anti-tumour necrosis factor 476. Schiller GJ, Slack J, Hainsworth JD, et al: Phase II multicenter study
alpha monoclonal antibody treatment for patients with myelodysplastic of arsenic trioxide in patients with myelodysplastic syndromes. J Clin
syndromes. Br J Haematol 116(2):334–337, 2002. Oncol 24(16):2456–2464, 2006.
456. Braun T, Fenaux P: Myelodysplastic syndromes (MDS) and auto- 477. Bejanyan N, Tiu R, Raza A: A phase 2 trial of combination therapy
immune disorders (AD): cause or consequence? Best Pract Res Clin with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid
Haematol 26(4):327–336, 2013. (TADA) in patients with overlap myelodysplastic/myeloproliferative
457. Biesma DH, van den Tweel JG, Verdonck LF: Immunosuppressive neoplasms (MDS/MPN) or primary myelofibrosis (PMF). Cancer
therapy for hypoplastic myelodysplastic syndrome. Cancer 79(8):1548– 118:3968–3976, 2012.
1551, 1997. 478. Sekeres MA, Maciejewski JP, Erba HP, et al: A Phase 2 study of com-
458. Molldrem JJ, Leifer E, Bahceci E, et al: Antithymocyte globulin for bination therapy with arsenic trioxide and gemtuzumab ozogamicin in
treatment of the bone marrow failure associated with myelodysplastic patients with myelodysplastic syndromes or secondary acute myeloid
syndromes. Ann Intern Med 137(3):156–163, 2002. leukemia. Cancer 117(6):1253–1261, 2011.
459. Saunthararajah Y, Nakamura R, Nam J-M, et al: HLA-DR15 (DR2) 479. Hast R, Axdorph S, Laurén L, et al: Absent clinical effects of retinoic
is overrepresented in myelodysplastic syndrome and aplastic anemia acid and isoretinoin treatment in the myelodysplastic syndrome.
and predicts a response to immunosuppression in myelodysplastic Hematol Oncol 7(4):297–301, 1989.
syndrome. Blood 100(5):1570–1574, 2002. 480. Ohno R, Naoe T, Hirano M, et al: Treatment of myelodysplastic
460. Sloand EM, Wu CO, Greenberg P, et al: Factors affecting response and syndromes with all-trans retinoic acid. Leukemia Study Group of the
survival in patients with myelodysplasia treated with immunosuppres- Ministry of Health and Welfare. Blood 81(5):1152–1154, 1993.
sive therapy. J Clin Oncol 26(15):2505–2511, 2008. 481. Schenk T, Chen WC, Göllner S, et al: Inhibition of the LSD1
461. Passweg JR, Giagounidis AAN, Simcock M, et al: Immunosuppressive (KDM1A) demethylase reactivates the all-trans-retinoic acid differen-
therapy for patients with myelodysplastic syndrome: a prospective ran- tiation pathway in acute myeloid leukemia. Nat Med 18(4):605–611,
domized multicenter phase III trial comparing antithymocyte globulin 2012.
plus cyclosporine with best supportive care–SAKK 33/99. J Clin Oncol 482. Search of: MDS AND (“low” or “intermediate”) NOT (“high-risk” or
29(3):303–309, 2011. “AML” or “acute myeloid leukemia”) | Open Studies | Exclude Unknown |
462. Sloand EM, Olnes MJ, Shenoy A, et al: Alemtuzumab treatment of Adult | Phase 1, 2, 3 - List Results - ClinicalTrials.gov [Internet].
intermediate-1 myelodysplasia patients is associated with sustained 483. Zhou L, Nguyen AN, Sohal D, et al: Inhibition of the TGF-beta recep-
improvement in blood counts and cytogenetic remissions. J Clin Oncol tor I kinase promotes hematopoiesis in MDS. Blood 112(8):3434–3443,
28(35):5166–5173, 2010. 2008.
463. Keyhani A, Jendiroba DB, Freireich EJ: Angiogenesis and leukemia. 484. Quesnel B, Guillerm G, Vereecque R, et al: Methylation of the
Leuk Res 25(8):639–645, 2001. p15(INK4b) gene in myelodysplastic syndromes is frequent and
464. Legros L, Slama B, Karsenti J-M, et al: Treatment of myelodysplastic acquired during disease progression. Blood 91(8):2985–2990,
syndromes with excess of blasts by bevacizumab is well tolerated and 1998.
is associated with a decrease of VEGF plasma level. Ann Hematol 485. Lin J, Yao D, Qian J, et al: Methylation status of fragile histidine triad
91(1):39–46, 2012. (FHIT) gene and its clinical impact on prognosis of patients with
465. Gupta P, Mulkey F, Hasserjian RP, et al: A phase II study of the myelodysplastic syndrome. Leuk Res 32(10):1541–1545, 2008.
oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ 486. Brakensiek K, Länger F, Schlegelberger B, et al: Hypermethylation of
ZK222584) in myelodysplastic syndrome: Cancer and Leukemia the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic
Group B study 10105 (Alliance). Invest New Drugs 31(5):1311–1320, syndrome. Br J Haematol 130(2):209–217, 2005.
2013. 487. Liu TX, Becker MW, Jelinek J, et al: Chromosome 5q deletion and
466. Erikci AA, Ozturk A, Karagoz B, et al: Results of combination therapy epigenetic suppression of the gene encoding alpha-catenin (CTNNA1)
with amifostine, pentoxifylline, ciprofloxacin and dexamethasone in in myeloid cell transformation. Nat Med 13(1):78–83, 2007.
patients with myelodysplastic syndrome and acute myeloid leukemia. 488. Shen L, Kantarjian H, Guo Y, et al: DNA methylation predicts survival
Hematology 13(5):289–292, 2008. and response to therapy in patients with myelodysplastic syndromes. J
467. List AF: Emerging data on IMiDs in the treatment of myelodysplastic Clin Oncol 28(4):605–613, 2010.
syndromes (MDS). Semin Oncol 32(4 Suppl 5):S31–S35, 2005. 489. Jones PA, Taylor SM: Cellular differentiation, cytidine analogs and
468. Vuylsteke J, Verloop MC, Drogendijk AC: Favourable effect of pyridox- DNA methylation. Cell 20(1):85–93, 1980.
ine and ascorbic acid in a patient with refractory sideroblastic anaemia 490. de Vos D: Epigenetic drugs: a longstanding story. Semin Oncol
and haemochromatosis. Acta Med Scand 169:113–123, 1961. 32(5):437–442, 2005.
469. Nagler A, Rikilis I, Tatarsky I, et al: Effect of 1,25-dihydroxyvitamin 491. Lyons RM, Cosgriff TM, Modi SS, et al: Hematologic response to three
D3 and 13-cis-retinoic acid on in vitro hematopoiesis in the myelodys- alternative dosing schedules of azacitidine in patients with myelodys-
plastic syndromes. J Lab Clin Med 110(2):237–244, 1987. plastic syndromes. J Clin Oncol 27(11):1850–1856, 2009.
470. Takami A, Nakao S, Ontachi Y, et al: Successful therapy of myelo- 492. Silverman LR, Demakos EP, Peterson BL, et al: Randomized controlled
dysplastic syndrome with menatetrenone, a vitamin K2 analog. Int J trial of azacitidine in patients with the myelodysplastic syndrome: a study
Hematol 69(1):24–26, 1999. of the cancer and leukemia group B. J Clin Oncol 20(10):2429–2440,
471. Tefferi A, Elliott MA, Steensma DP, et al: Amifostine alone and in 2002.
combination with erythropoietin for the treatment of favorable myelo- 493. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al: Efficacy of azacitidine
dysplastic syndrome. Leuk Res 25(2):183–185, 2001. compared with that of conventional care regimens in the treatment
472. Andreeff M, Stone R, Michaeli J, et al: Hexamethylene bisacetamide of higher-risk myelodysplastic syndromes: a randomised, open-label,
in myelodysplastic syndrome and acute myelogenous leukemia: a phase III study. Lancet Oncol 10(3):223–232, 2009.